Free Trial

Aclarion Q2 2023 Earnings Report

Aclarion logo
$12.12 -1.97 (-14.01%)
As of 03/28/2025 04:00 PM Eastern

Aclarion EPS Results

Actual EPS
-$964.80
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Aclarion Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aclarion Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Remove Ads

Aclarion Earnings Headlines

Aclarion, Inc. (NASDAQ:ACON) Short Interest Down 73.9% in March
Aclarion announces 1-for-27 reverese stock split
The Dirty Secret About Gold Mining Stocks...
Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy shareholder value over time. Even as gold prices rise.
Aclarion Provides Shareholder Update
See More Aclarion Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aclarion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aclarion and other key companies, straight to your email.

About Aclarion

Aclarion (NASDAQ:ACON), a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

View Aclarion Profile

More Earnings Resources from MarketBeat